Allergy Therapeutics PLC Appointment of Head of Clinical Science
November 04 2014 - 02:02AM
RNS Non-Regulatory
TIDMAGY
Allergy Therapeutics PLC
04 November 2014
4 November 2014
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Appointment of Dr Daphne Tsitoura as Head of Clinical
Science
Allergy Therapeutics, the fully integrated specialty
pharmaceutical company specialising in allergy vaccines, today
announces the appointment of Dr Daphne Tsitoura as Head of Clinical
Science leading the Clinical Development team in Munich and
Worthing from the 10(th) November, reporting to Professor Tim
Higgenbottam.
Dr Tsitoura joins Allergy Therapeutics from GSK, where she has
spent the last eight years as Principal Physician in the
Respiratory Therapeutic Area in the GSKs' Stevenage Research Centre
UK and has maintained a clinical link with allergy as an associate
Allergist at University College Hospital London UK.
Previously she has held roles of Principal Immunologist at the
Institute of Biomedical Research Academy of Athens, Consultant
Physician / Chief of the Allergy Unit at the Henry Dunant Hospital
Athens, senior fellow in immunology and allergy at Stanford
University School of Medicine Palo Alto USA, and associate
professor in Respiratory Medicine College of Physicians and
Surgeons Columbia University New York.
Tim Higenbottam, R & D Director said:
"With an impressive career in medicine development and allergy,
Daphne brings to Allergy Therapeutics a passion and drive to
enhance the ease of use of allergy vaccines. She has a great depth
of understanding of the therapeutic methods of modulation of the
innate immune system to optimise allergy therapies. Her expertise
will lend enormous support and strengthen our team of
pharmaceutical experts and drive the research to gain approval of
our Pollinex Quattro ultra-short course allergy vaccines in Europe
and US."
-Ends-
For further information
Allergy Therapeutics +44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
www.allergytherapeutics.com
Peel Hunt LLP +44 (0) 20 7418 8900
James Steel / Clare Terlouw
FTI Consulting +44 (0) 20 3727 1000
Simon Conway / Victoria Foster Mitchell /
Mo Noonan
Notes to editors
About Allergy Therapeutics
Allergy Therapeutics is a specialty pharmaceutical company
focused on allergy vaccination. It has a growing business with
revenue of GBP42million achieved mainly in Europe through its own
sales and marketing infrastructure and further afield through
distributors.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAXFDEFELFFF
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2023 to Mar 2024